InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.710

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$299 Entitlement Offer Booklet 17 Jul 2026 9:36AM $0.730 $0.710 fallen by 2.74%
$299 Cleansing Notice 15 Jul 2026 9:25AM $0.755 $0.710 fallen by 5.96%
$299 Proposed issue of securities - SPL 15 Jul 2026 9:20AM $0.755 $0.710 fallen by 5.96%
$299 Entitlement Offer Investor Presentation 15 Jul 2026 9:15AM $0.755 $0.710 fallen by 5.96%
$299 Fully Underwritten Entitlement Offer to Raise $32 Million 15 Jul 2026 9:10AM $0.755 $0.710 fallen by 5.96%
$299 Quarterly Activities Report and Appendix 4C 15 Jul 2026 9:03AM $0.755 $0.710 fallen by 5.96%
$299 DEP HER2 Investor Webinar 7 Jul 2026 3:26PM $0.720 $0.710 fallen by 1.39%
$299 DEP milestone triggers partner option fee 3 Jul 2026 9:29AM $0.710 $0.710 fallen by 0%
$299 Positive DEP HER2-Lu preclinical data support Phase 1 entry 2 Jul 2026 9:22AM $0.710 $0.710 fallen by 0%
$299 DEP radiopharmaceutical data supports patent application 2 Jul 2026 9:20AM $0.710 $0.710 fallen by 0%
$299 Becoming a substantial holder 23 Jun 2026 6:06PM $0.695 $0.710 risen by 2.16%
$299 Becoming a substantial holder 17 Jun 2026 8:28AM $0.690 $0.710 risen by 2.90%
$299 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 10:15AM $0.705 $0.710 risen by 0.71%
$299 FDA confirms path to DEP HER2 first-in-human study 21 Apr 2026 9:40AM $0.680 $0.710 risen by 4.41%
$299 Becoming a substantial holder 15 Apr 2026 8:24AM $0.535 $0.710 risen by 32.71%
$299 Application for quotation of securities - SPL 7 Apr 2026 8:32AM $0.500 $0.710 risen by 42%
$299 Ceasing to be a substantial holder 12 Mar 2026 1:29PM $0.380 $0.710 risen by 86.84%
$299 Becoming a substantial holder 3 Mar 2026 8:04PM $0.400 $0.710 risen by 77.50%
$299 Half Yearly Report and Accounts 18 Feb 2026 8:37AM $0.480 $0.710 risen by 47.92%
$299 Ceasing to be a substantial holder 18 Feb 2026 8:10AM $0.480 $0.710 risen by 47.92%
$299 Ceasing to be a substantial holder 10 Feb 2026 3:42PM $0.410 $0.710 risen by 73.17%
$299 Change in substantial holding 10 Feb 2026 8:17AM $0.400 $0.710 risen by 77.50%
$299 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 10:01AM $0.350 $0.710 risen by 102.86%
$299 Application for quotation of securities - SPL 7 Jan 2026 1:03PM $0.365 $0.710 risen by 94.52%
$299 Notification of cessation of securities - SPL 7 Jan 2026 12:58PM $0.360 $0.710 risen by 97.22%

1 - 25 of 863 results

Page 1 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.